Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A prediction model for response to immune checkpoint inhibition in advanced melanoma.
van Duin IAJ, Verheijden RJ, van Diest PJ, Blokx WAM, El-Sharouni MA, Verhoeff JJC, Leiner T, van den Eertwegh AJM, de Groot JWB, van Not OJ, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Haanen JBAG, Hospers GAP, Piersma D, van Rijn RS, van der Veldt AAM, Vreugdenhil G, Wouters MWJM, Stevense-den Boer MAM, Boers-Sonderen MJ, Kapiteijn E, Suijkerbuijk KPM, Elias SG. van Duin IAJ, et al. Among authors: verheijden rj. Int J Cancer. 2024 May 15;154(10):1760-1771. doi: 10.1002/ijc.34853. Epub 2024 Jan 31. Int J Cancer. 2024. PMID: 38296842
BRAF/MEK inhibitor rechallenge in advanced melanoma patients.
Van Not OJ, van den Eertwegh AJM, Haanen JB, van Rijn RS, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, de Groot JWWB, Hospers GAP, Kapiteijn E, Bloem M, Piersma D, Stevense-den Boer M, Verheijden RJ, van der Veldt AAM, Wouters MWJM, Blokx WAM, Suijkerbuijk KPM. Van Not OJ, et al. Among authors: verheijden rj. Cancer. 2024 May 1;130(9):1673-1683. doi: 10.1002/cncr.35178. Epub 2024 Jan 10. Cancer. 2024. PMID: 38198485
Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition.
van Eijs MJM, Verheijden RJ, van der Wees SA, Nierkens S, van Lindert ASR, Suijkerbuijk KPM, van Wijk F; UNICIT consortium. van Eijs MJM, et al. Among authors: verheijden rj. Cancer Immunol Immunother. 2023 Dec;72(12):4049-4064. doi: 10.1007/s00262-023-03541-0. Epub 2023 Oct 4. Cancer Immunol Immunother. 2023. PMID: 37794264 Free PMC article.
Highly multiplexed spatial analysis identifies tissue-resident memory T cells as drivers of ulcerative and immune checkpoint inhibitor colitis.
van Eijs MJM, Ter Linde JJM, Baars MJD, Amini M, Laclé MM, Brand EC, Delemarre EM, Drylewicz J, Nierkens S, Verheijden RJ, Oldenburg B, Vercoulen Y, Suijkerbuijk KPM, van Wijk F. van Eijs MJM, et al. Among authors: verheijden rj. iScience. 2023 Sep 11;26(10):107891. doi: 10.1016/j.isci.2023.107891. eCollection 2023 Oct 20. iScience. 2023. PMID: 37766980 Free PMC article.
Prognostic value of Lynch syndrome, BRAFV600E , and RAS mutational status in dMMR/MSI-H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts.
Zwart K, van der Baan FH, Cohen R, Aparicio T, de la Fouchardiére C, Lecomte T, Punt CJA, Sefrioui D, Verheijden RJ, Vink GR, Wensink GE, Zaanan A, Koopman M, Tougeron D, Roodhart JML. Zwart K, et al. Among authors: verheijden rj. Cancer Med. 2023 Aug;12(15):15841-15853. doi: 10.1002/cam4.6223. Epub 2023 Jun 16. Cancer Med. 2023. PMID: 37326121 Free PMC article.
Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma.
van Duin IAJ, Elias SG, van den Eertwegh AJM, de Groot JWB, Blokx WAM, van Diest PJ, Leiner T, Verhoeff JJC, Verheijden RJ, van Not OJ, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Haanen JBAG, Hospers GAP, Kamphuis AM, Piersma D, van Rijn RS, van der Veldt AAM, Vreugdenhil G, Wouters MWJM, Stevense-den Boer MAM, Boers-Sonderen MJ, Kapiteijn E, Suijkerbuijk KPM. van Duin IAJ, et al. Among authors: verheijden rj. Int J Cancer. 2023 Jun 15;152(12):2493-2502. doi: 10.1002/ijc.34479. Epub 2023 Mar 4. Int J Cancer. 2023. PMID: 36843274
Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma.
van Not OJ, Verheijden RJ, van den Eertwegh AJM, Haanen JBAG, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, de Groot JB, Hospers GAP, Kamphuis AM, Kapiteijn E, May AM, de Meza MM, Piersma D, van Rijn R, Stevense-den Boer MA, van der Veldt AAM, Vreugdenhil G, Blokx WAM, Wouters MJM, Suijkerbuijk KPM. van Not OJ, et al. Among authors: verheijden rj. JAMA Oncol. 2022 Dec 1;8(12):1794-1801. doi: 10.1001/jamaoncol.2022.5041. JAMA Oncol. 2022. PMID: 36301521 Free PMC article.
18 results